InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-22.1%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Mazar Andrew Paul, Directeur Scientifique. Insider active across 1 company, notably Monopar Therapeutics. In total, 9 reports have been recorded. Regulator: SEC (Form 4). The full history is openly available.
Declarations9 total
1,606 sharesCommon StockSEC:0001654954-22-004490:0
1,937 sharesCommon StockSEC:0001654954-22-000130:0
1,606 sharesCommon StockSEC:0001654954-22-000129
1,606 sharesCommon StockSEC:0001654954-22-000129:0
1,937 sharesCommon StockSEC:0001654954-22-000130
1,606 sharesCommon StockSEC:0001654954-21-010720
1,606 sharesCommon StockSEC:0001654954-21-010720:0
3,212 sharesCommon StockSEC:0001654954-21-007595:0
3,212 sharesCommon StockSEC:0001654954-21-007595
9 of 9 declarations
About Mazar Andrew Paul
Mazar Andrew Paul is the Chief Scientific Officer at Monopar Therapeutics. He oversees the company's research and development programs, ensuring innovation and product quality. His role is crucial for the success of the organization's scientific initiatives.
